Melanoma Research Alliance Awards
The Melanoma Research Alliance supports both individual investigator and collaborative team projects focused on translational, innovative research that will impact the prevention, diagnosis, staging, and treatment of melanoma in the near and intermediate future. Current funding opportunities include:
- Young Investigator Awards for Women in Scientific Research support early career female researchers who are conducting cutting-edge melanoma research. The awardee will receive up to $225,000 total over three years to support projects with the potential to lead to transformative advances in prevention, detection, diagnosis, staging or treatment of melanoma. For this award, the PI must be a woman.
- Young Investigator Awards support early career scientists with novel ideas into the field of melanoma, thereby recruiting and supporting the next generation of melanoma research leaders. Awardees will be provided up to $75,000 per year for three years (up to $225,000 total) to accomplish innovative and creative, preclinical, translational, and/or early clinical research projects.
- Established Investigator Awards support senior investigators with a record of scientific productivity and accomplishment and who are past the initial four years of their first academic faculty appointment. Investigators with an established record of scientific productivity will receive up to $100,000 per year for two to three years (up to $300,000 total) from MRA to conduct projects supported by preliminary data.
Application Due Date: November 17, 2017
Mallinckrodt Scholar Award
Emory University has been invited to nominate two (2) candidates for the Edward Mallinckrodt, Jr Foundation Mallinckrodt Scholar Award. The Scholar Award provides $100,000 per year for a period of four years. Eligible faculty members must hold M.D. and/or Ph.D. degrees and be in their 5th to 8th year of a tenure-track position. Interested applicants should submit an abstract of their proposed projects (not to exceed 2 pages) and an NIH-style biosketch to Holly Sommers via email (email@example.com).
Internal Due Date: November 27, 2017
Foundation Due Date: January 15, 2018
Contact: Holly Sommers
ASCO Resident Travel Award for Underrepresented Populations
The Conquer Cancer Foundation of ASCO Resident Travel Award for Underrepresented Populations provides financial support for residents from underrepresented populations to attend ASCO’s Annual Meeting. This award allows physician residents interested in a career in oncology to travel to the ASCO Annual Meeting, where they will have the opportunity to meet oncologists and to learn more about career option in the field of oncology. The award includes a $1,500 travel advance and complimentary ASCO Annual Meeting registration. The number of Resident Travel Awards in each funding cycle is not predetermined by the Conquer Cancer Foundation. Awards are given based on individual merit and availability of funds.
Application Due Date: December 1, 2017
Damon Runyon Clinical Investigator Award
The Damon Runyon Clinical Investigator Award supports independent early-career physician-scientists (MDs or MD/PhDs) conducting disease-oriented research that demonstrates a high level of innovation and creativity. The award will provide $450,000 over three years in financial support for the investigator’s scientific needs, as well as assistance with certain research costs such as the purchase of equipment. The Foundation will also retire up to $100,000 of any medical school debt still owed by the awardee.
Eligible applicants must be:
- U.S. citizens or permanent legal residents
- Independent assistant professors (or equivalent) within the first four years of their initial full faculty appointment (cut-off July 2014)
- Nominated by their institution
- MD or MD/PhD degree-holders from an accredited institution who has completed their subspecialty training
- U.S. board-eligible with a valid, active U.S. medical license at the time of application
- Committed to spending 80% of their time conducting research (rare exceptions apply)
- Mentored by an eligible faculty member who is not concurrently mentoring another Damon Runyon Clinical Investigator Award applicant.
*View award details for complete eligibility requirements.
Letters of Intent (not to exceed 2 pages) are due Friday, December 1, 2017 via email to firstname.lastname@example.org. Letters of Intent should also include the PI’s NIH Biosketch, a proposed title for the research project, and a brief 1-2 page abstract of the proposed research project. The selected investigators will be notified and invited to submit a full application by Winship.
Letter of Intent Due Date: December 1, 2017
Winship Announcement of Nominee Selection: Mid December 2017
Damon Runyon Application Due Date: February 1, 2018
Alex's Lemonade Stand - Epidemiology Grants
Alex’s Lemonade Stand Epidemiology Grants are $100,000 per year for two years. Funding allows investigators to pursue research studies in human populations, using epidemiological approaches, in order to significantly contribute to the understanding of childhood cancers. Hypothesis-driven research may focus on risk factors, early detection, prevention, effectiveness and treatment outcomes. Awards are $100,000 per year for two years.
Application Due Date: December 15, 2017
Pancreatic Cancer Action Network Grants
The Pancreatic Cancer Action Network offers grants for basic, translational and clinical research in pancreatic cancer to scientists and clinicians at various career levels.
2018 Catalyst Grant
Supports a junior faculty to conduct pancreatic cancer research and establish successful career paths in the field with a $500,000 grant over three years. Proposed research may be basic, translational, clinical or epidemiological in nature and must have direct applicability and relevance to pancreatic cancer.
Application Due Date: December 15, 2017
2018 Translational Research Grant
Supports independent investigators conducting high priority pancreatic cancer research that is poised for important translational next steps with a $500,000 grant over two years. Proposed research should aim to identify novel targets and approaches to the treatment of pancreatic cancer or understand and circumvent treatment resistance.
Application Due Date: January 15, 2018
NCI Clinical and Translational Exploratory/Developmental Studies (R21)
The National Cancer Institute has issued this funding opportunity to promote innovative pre-clinical, early-phase clinical, and correlative studies that are hypothesis-driven and based upon established basic cancer research discoveries. By using the R21 mechanism, this funding opportunity will support exploratory/developmental projects in the advancement of novel anti-cancer agents, diagnostic tools, and clinical approaches in treatment, symptom management, and prevention of common or rare tumors. These studies may involve considerable risk, but may lead to a breakthrough in a particular area, and/or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).
Application Due Date: February 20, 2018
Paul Calabresi Career Development Award for Clinical Oncology (K12)
This funding opportunity announcement encourages applications for institutional research career development (K12) programs from applicant organizations that propose to promote the training and career development of clinical trials researchers. It is intended to increase the number of clinicians (MDs, DOs, PharmDs, nurses with PhDs or equivalent) and non-clinician postdoctoral researchers trained to design and test clinical therapeutic research protocols in clinical trial settings (pilot/Phase I, Phase II, and Phase III clinical trials).Application Due Date: June 15, 2018
Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery
The Behavioral Research Program, Epidemiology and Genomics Research Program, and Healthcare Delivery Research Program of the National Cancer Institute’s Division of Cancer Control and Population Sciences have collaborated on the release of a program announcement to study the utilization, adherence, and delivery of oral anticancer agents. Specifically, this program announcement encourages research grant applications to:
- Assess and describe the current state of oral anticancer medication utilization, delivery, and adherence;
- Identify structural, systemic, and psychosocial barriers to adherence; and
- Develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized.